Mr. Christopher Viehbacher is president and CEO of Biogen, a multinational biotechology company. He is also a founding partner of Gurnet Point Capital, a Boston-based investment fund associated with the Bertarelli family with a $2 billion capital allocation. He is also a member of the Board of Pure Tech Health plc; the Chairman of Vedanta, a Pure Tech portfolio company; and a member of the Board of Trustees of Northeastern University.
Mr. Viehbacher is the former CEO and member of the board of directors of Sanofi, a Fortune 50 Biopharmaceutical company based in Paris. He was also the Chairman of the Board of Genzyme in Boston.
Prior to joining Sanofi, Mr. Viehbacher spent 20 years with GlaxoSmithKline in Germany, Canada, France and, latterly, the US as President of GSK North America. He was a member of the board of directors of GSK plc in London and Co-President of GSK’s Portfolio Management Board. He began his career with Price Waterhouse after graduating with a degree in Commerce at Queen’s University in Canada.
Mr. Viehbacher has been a strong advocate for the health care industry. Current and past advocacy roles include: Former Co-chair with Bill Gates for the CEO Roundtable on Neglected Diseases, Immediate Past Chairman of the CEO Roundtable on Cancer, Past Chairman of the Board of the Pharmaceutical Research and Manufacturers of America in Washington, and President of the European Federation of Pharmaceutical Industries and Associations in Brussels. He was Chair of the Health Governors at World Economic Forum and Co-chair of a WEF initiative to create a Global Charter for Healthy Living and Member of the International Business Council.
Mr. Viehbacher has in the past served on various advisory groups at MIT, Duke University and Queen’s University at Kingston, Ontario. He has received the Pasteur Foundation Award for outstanding commitment to safeguarding and improving health worldwide, and France’s highest civilian honor, the Legion d’Honneur.